Macro Economic Insights - The government is intensifying efforts to clear overdue corporate payments and wages, focusing on key regions and implementing special bonds to support this initiative [6][7] - The central bank has introduced a series of monetary policies, including a 0.25 percentage point reduction in relending and rediscount rates, and plans to maintain a loose monetary stance throughout 2026 [7][17] - The real estate policy includes extending tax incentives for residential property transactions and lowering the minimum down payment for commercial property loans to 30% [7] Industry Insights Computer Industry - Alibaba is fully integrating its Qianwen App into its ecosystem, enhancing its capabilities as an AI shopping assistant and potentially becoming a major entry point for AI services [50] - The launch of "Ant Health Assistant" and "Lingguang," a multimodal AI assistant, indicates Alibaba's strong positioning in the AI sector, with significant user engagement [51][52] - Investment opportunities in AI applications are highlighted, with recommendations for companies benefiting from this trend [53] Machinery Industry - The use of polyurethane TPU materials in humanoid robots is emphasized, showcasing their advantages in safety and shock absorption, which are critical for the mass production of robots [55][56] - The TPU market is expected to grow significantly due to its application in humanoid robots, with a projected market space exceeding 3 billion yuan as production scales up [58] Non-Banking Financial Sector - The regulatory environment for derivatives is becoming more transparent, which may benefit leading brokerage firms as restrictions on scale are expected to ease [6] - The financial sector is experiencing a "slow bull" phase, with positive performance in brokerage and insurance businesses [6] Chemical Industry - The polyester filament industry is entering a new round of production cuts, while the supply-demand dynamics for glyphosate are improving, leading to price increases [6] Automotive Industry - China's heavy truck sales are projected to reach 1.145 million units by 2025, indicating a robust market outlook [6] Food and Beverage Industry - Moutai is deepening market reforms, and the value of Bai Run shares is becoming more apparent, suggesting potential investment opportunities [6] Pharmaceutical Industry - The focus remains on innovative drug sectors, with continued recommendations for investment in this area [6] Trade and Export - China's exports have shown unexpected growth, with a year-on-year increase of 6.6% in December, driven by high-tech products and diversified markets [41][42][45]

Investment Rating - The industry rating is "Outperform the Market" indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% in the next 6 months [69]. Core Insights - The report highlights a strong recovery in investment and financing activities in the CXO sector, with significant increases in both primary and secondary market financing in the biotech industry [4][18][23]. - The JPM conference revealed that many CXO companies expressed optimism for 2026, driven by project structure optimization, improved operational efficiency, and sustained customer demand [4][28]. - The report emphasizes the importance of technological innovation in the pharmaceutical sector for 2026, with a focus on innovative drugs and medical devices [5]. Summary by Sections Investment and Financing Trends - Since September 2025, overseas primary market financing has shown strong recovery, with a total of $8.72 billion in Q4 2025, a year-on-year decrease of 2.4% but a quarter-on-quarter increase of 21% [4][18]. - In January 2026, the total financing amount reached $3.34 billion, indicating a significant recovery compared to previous months [4][18]. - The secondary market for biotech also saw a robust recovery, with Q4 2025 financing totaling $19.28 billion, a year-on-year increase of 111% and a quarter-on-quarter increase of 149.5% [23][26]. Market Performance Review - During the week of January 12-16, 2026, the CITIC Pharmaceutical Index fell by 0.72%, underperforming the CSI 300 Index by 0.2 percentage points, ranking 16th among CITIC's primary industry classifications [3][32]. - The pharmaceutical sector has shown a year-to-date increase of 6.9% in 2026, outperforming the CSI 300 Index by 4.7 percentage points, ranking 7th among industry classifications [3][32]. - The top-performing stocks during this week included Baolait (up 48.8%), Hualan Biological (up 32.7%), and Tianzhihang (up 27.7%) [47]. Company Highlights from JPM Conference - WuXi AppTec reported a revenue of 45.5 billion yuan in 2025, a year-on-year increase of 21.4%, and a net profit of 15 billion yuan, up 41.3% [30]. - WuXi Biologics achieved significant growth with a revenue increase driven by its dual antibody business, which saw a year-on-year growth of 120% [30]. - Lonza expects a revenue growth of 20-21% in 2025, with a core EBITDA margin of 30-31% [30]. Investment Strategy - The report suggests focusing on innovative drugs, particularly those with revenue realization and unexpected business development outcomes, as well as cutting-edge technology platforms like gene therapy and CAR-T [5]. - In the medical device sector, attention should be given to equipment replenishment and bidding, particularly in surgical robots and endoscopes [5].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Core Viewpoint - The Hong Kong stock market continues to adjust, with the pharmaceutical sector declining alongside the market, particularly affected by a short-term cooling of AI medical concepts [1][12]. Group 1: Market Performance - The Hong Kong Medical ETF Huabao (159137) fell by 0.93%, marking two consecutive days of decline, while the Hong Kong Innovation Drug ETF (520880) dropped by 1.08% [1][12]. - The medical sector saw 13 stocks rise and 37 fall, with Ark Health, a hot stock in AI medical concepts, leading the decline at 6.98%, and Alibaba Health also falling by 5.16% [2][13]. - The Hong Kong Medical Theme Index achieved a record nine consecutive days of gains before experiencing a pullback, with the Huabao ETF having a cumulative increase of 6.9% in its first week, outperforming the Hang Seng Index, which rose by 2.34% [3][14]. Group 2: Sector Analysis - The Huabao Medical ETF covers 50 leading stocks across various medical fields, including CXO, AI medical, medical devices, and innovative drugs, indicating a comprehensive approach to capturing market trends [5][16]. - The medical sector has shown significant recovery since 2026, driven by hot themes like brain-computer interfaces and AI medical, with increasing investment value [6][17]. - The CXO sector is expected to see a recovery in demand, with WuXi AppTec forecasting a net profit of 19.151 billion yuan for 2025, reflecting a year-on-year growth of approximately 102.65% [18]. Group 3: Investment Opportunities - Analysts suggest focusing on innovative overseas expansion and hard technology sectors, such as AI medical and brain-computer interfaces, while monitoring the expansion of medical insurance and essential drug directories [18]. - The Huabao Medical ETF is highlighted as a high-elasticity investment tool for capturing new opportunities in the medical field, particularly in AI medical and innovative drug supply chains [18]. - The largest medical ETF in the A-share market, focusing on medical devices and services, is also noted for its significant weight in AI medical and brain-computer interface concept stocks [18].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights that the performance of leading CXO companies is impressive, with significant growth expected in 2025. Notable companies such as WuXi AppTec, WuXi Biologics, and CRDMO are projected to see substantial revenue increases, with WuXi AppTec's revenue expected to grow by approximately 21.4% year-on-year, and net profit expected to increase by 102.7% [3][12] - The demand side is gradually improving, with the global healthcare industry expected to see a total investment of $63.882 billion in 2025, reflecting a year-on-year growth of 10.13%. The domestic market in China is also showing signs of recovery, with total financing in the healthcare sector expected to reach 73.777 billion yuan, a year-on-year increase of 39.05% [4][18] Summary by Sections Section 1: Performance of Leading CXO Companies - The report indicates that leading CXO companies are expected to continue their strong performance into 2025, with significant revenue and profit growth anticipated. WuXi AppTec is expected to achieve a revenue of approximately 45.456 billion yuan, with a year-on-year growth of 21.4% and a net profit increase of 102.65% [12][13] - WuXi Biologics is projected to benefit from the ADC sector, with revenue growth exceeding 45% and gross profit growth over 70% [3][12] - CRDMO is also expected to see a revenue increase of 13% to 16%, with net profit growth of 36% to 41% [14] Section 2: Demand Side Improvement - The global healthcare investment is expected to reach $63.882 billion in 2025, with a notable recovery in the second half of the year, showing a year-on-year increase of 10.13% [4][18] - In China, the total financing in the healthcare sector is projected to reach 73.777 billion yuan, marking a 39.05% year-on-year increase, with a significant rise in new drug IND applications [18][19] - The report notes that the average R&D investment among the top 30 global pharmaceutical companies is expected to grow steadily, with an average of $4.172 billion in the first three quarters of 2025, reflecting a year-on-year increase of 3.45% [4][20] Section 3: Market Trends - In the second week of January 2026, the pharmaceutical and biotechnology sector saw a decline of 0.68%, underperforming the CSI 300 index by 0.11 percentage points [5][24] - The medical R&D outsourcing sector experienced the highest growth, with an increase of 3.69%, while the vaccine sector faced the largest decline, dropping by 3.43% [5][25] - The report also highlights that the clinical CRO sector is expected to see a significant improvement in performance, with companies like Tigermed and Proprius maintaining steady growth in both revenue and orders [23]

Investment Rating - The industry rating is "Outperform the Market" [7] Core Insights - The report highlights a strong recovery in investment and financing activities in the CXO sector, with significant growth in both primary and secondary markets for biotech [4][18][23] - The JPM conference indicated a positive outlook for 2026, with companies expressing optimism about demand recovery and operational efficiency improvements [4][28] - The report emphasizes the importance of technological innovation in the pharmaceutical sector for 2026, focusing on innovative drugs and medical devices [5][32] Summary by Sections Investment Opportunities and Trends - Primary market financing for overseas biotech reached $8.72 billion in Q4 2025, showing a year-on-year decrease of 2.4% but a quarter-on-quarter increase of 21% [4][18] - In January 2026, primary market financing totaled $3.34 billion, indicating a strong recovery [4][18] - Secondary market financing for overseas biotech in Q4 2025 was $19.28 billion, a year-on-year increase of 111% and a quarter-on-quarter increase of 149.5% [4][23] - The report notes that companies like WuXi AppTec and Danaher exceeded performance expectations, with a general recovery in demand for Pharma and Biotech orders [4][28] Market Performance Review - The CITIC Pharmaceutical Index fell by 0.72% from January 12 to January 16, 2026, underperforming the CSI 300 Index by 0.2 percentage points [3][32] - The pharmaceutical sector has seen a 6.9% increase since the beginning of 2026, outperforming the CSI 300 Index by 4.7 percentage points [3][32] - The top-performing stocks during this period included Baolai Te (+48.8%), Hualan Biological Engineering (+32.7%), and Tianzhihang (+27.7%) [3][47] Company Performance and Recommendations - The report suggests focusing on companies such as WuXi AppTec, Beigene, and others for potential investment opportunities in 2026 [5][54] - The report outlines a strategy for innovative drugs, emphasizing revenue realization, unexpected business development, and cutting-edge technology platforms [5][32] - The medical device sector is highlighted for its potential in equipment replenishment and innovative consumables benefiting from centralized procurement [5][32]

证券研究报告 2026 年 01 月 17 日 湘财证券研究所 行业研究 医疗服务行业周报 政策力促银发经济升级，两大方向直接受益 --医疗服务行业周报 1.12-1.16 相关研究： 核心要点： 本周医药生物下跌 0.68%，涨跌幅排名位列申万一级行业第 19 位 根据 Wind 数据，本周申万一级行业医药生物下跌 0.68%，涨幅排名位列申 万 31 个一级行业第 19 位。沪深 300 指数下跌 0.57%，医药跑输沪深 300 指数 0.11 个百分点。申万医药生物二级子行业医疗服务 II 报收 7048.32 点，上涨 3.29%；中药 II 报收 6414.65 点，下跌 1.00%；化学制药Ⅱ报收 13656.41 点，下跌 2.40%；生物制品Ⅱ报收 6506.32 点，下跌 1.21%；医 药商业Ⅱ报收 5587.64 点，下跌 2.33%；医疗器械 II 报收 6896.75 点，下 跌 0.22%。 根据 Wind 数据，从医疗服务板块公司的表现来看，表现居前的公司有： 美年健康（+25.0%）、迪安诊断（+16.3%）、泓博医药（+13.0%）、兰卫医 学（+12.2%）、诺思格（+1 ...

Group 1 - Recent star companies in technology, consumer, and high-end manufacturing sectors are driving market momentum, enhancing the linkage between capital markets in both regions [1] - Notable A-share companies are making significant progress in their listings in Hong Kong, including Longqi Technology, which is currently in the process of going public and has attracted investments from major institutions [2] - Dongpeng Beverage has successfully passed the listing hearing in Hong Kong and has maintained a leading market share in China's functional beverage market, increasing from 15% in 2021 to 26.3% in 2024 [2] Group 2 - The AH premium index has shown slight fluctuations, reflecting a recent increase in A-share performance compared to H-shares, with the index reported at 120.43 points as of January 16, up from 115.44 points at the end of the previous year [6] - The recent trend of A-share companies listing in Hong Kong has led to a decrease in the AH premium index, as high-quality A-share companies enhance liquidity in the Hong Kong market [6] - Currently, there are 37 companies with an AH premium exceeding 100%, with Zhejiang Shibao leading at a premium rate of 360.30% [7] Group 3 - Multiple factors are contributing to the current trend of A-share companies listing in Hong Kong, including a stronger A-share market driven by high-tech sectors, while the Hong Kong market remains influenced by traditional sectors [8] - The liquidity situation in the A-share market, supported by long-term capital allocations and individual investors leveraging, contrasts with the Hong Kong market, which is affected by external risk preferences [8] - The Hong Kong IPO market is expected to remain active in 2026, with a significant number of companies in the pipeline, including 105 A-share projects [9]

Group 1 - A-share companies have seen a resurgence in Hong Kong listings since Q4 2025, with a total of 10 new companies added to the A+H sector, including Zhaoyi Innovation and OmniVision Technologies [1] - Notable companies such as Longqi Technology, Lanke Technology, Desay SV, Dongpeng Beverage, and Guoen Co. are accelerating their listing processes [1] - The recent trend has strengthened the linkage between the two capital markets, making the differentiation in AH share premium levels a focal point for the market [1] Group 2 - Longqi Technology, a leading ODM manufacturer, is currently in the process of going public, with an expected listing date of January 22, raising approximately 440.2 million HKD [1] - Lanke Technology has passed its listing hearing and plans to raise 900 million USD for technology research and development, with Alibaba and Morgan Asset Management as cornerstone investors [1] - Dongpeng Beverage has successfully passed the main board listing hearing in Hong Kong, holding a 26.3% market share in China's functional beverage market as of 2024, up from 15% in 2021 [2] Group 3 - The AH share premium index has shown a downward trend since 2025, attributed to the influx of quality A-share companies enhancing liquidity in the Hong Kong market [3] - As of January 16, the AH share premium index was reported at 120.43 points, reflecting a slight increase from the low of 115.44 points at the end of the previous year [3] - Among the newly listed A+H companies, the premium rates mostly range from 20% to 80%, with some companies like Guanghetong showing a premium exceeding 117.71% [3][4] Group 4 - There are currently 37 companies with an AH premium exceeding 100%, with Zhejiang Shibao leading at a premium rate of 360.30% [4] - The ongoing trend of A-share companies listing in Hong Kong is expected to continue, supported by multiple factors, as noted by various institutions and brokerages [5] Group 5 - Since the beginning of 2026, A-shares have outperformed Hong Kong stocks, leading to fluctuations in the AH share premium index [6] - The strong performance of A-shares is primarily driven by new listings in high-tech and advanced manufacturing sectors, while the Hong Kong market remains dominated by traditional sectors [6] - The current environment suggests that while Hong Kong stocks are underperforming, the AH premium index is stabilizing, indicating a preference for quality H-shares among domestic investors [6] Group 6 - The Hong Kong Stock Exchange currently has 357 companies in the listing queue, with 105 projects from A-share companies, indicating a robust pipeline for IPOs in 2026 [7]

Core Viewpoint - The A-share market is experiencing an increase in performance announcements as the deadline for annual report forecasts approaches, with over 280 companies having disclosed their 2025 annual report forecasts by January 16, 2023, accounting for nearly 5.2% of the total market [1][10]. Group 1: Performance Forecasts - Nearly 140 companies have reported positive forecasts for 2025 net profit attributable to shareholders, representing about 47.6% of all companies that have disclosed forecasts. The breakdown includes 26.9% expecting profit increases, 14.7% slight increases, 5.6% turning profitable, and 0.3% continuing profitability [3][12]. - Approximately half of the companies are expected to incur losses in 2025, with categories including continued losses (19.6%), first-time losses (10.5%), reduced losses (8.7%), increased losses (4.9%), and profit reductions (4.5%) [3][12]. Group 2: Industry Distribution - The sectors with the highest number of companies reporting positive forecasts include basic chemicals, electronics, automotive, biomedicine, and machinery, which together account for nearly 56.6% of the positive forecasted companies [3][12]. - In terms of loss forecasts, the sectors with the highest concentration of expected losses include electronics, electrical equipment, construction decoration, machinery, and biomedicine, with coal, steel, construction materials, and real estate also showing significant loss ratios [4][13]. Group 3: Notable Companies - Eleven companies are expected to report net profits exceeding 5 billion yuan for 2025, with Zijin Mining leading at 51 billion yuan, followed by Luoyang Molybdenum, Luxshare Precision, WuXi AppTec, Muyuan Foods, and Baofeng Energy, all exceeding 10 billion yuan [7][16]. - Among the companies with the highest expected profit growth, 48 are projected to see their profits double, with Huisheng Biological, Zhongtai Shares, SAIC Motor, Baive Storage, and Huazheng New Materials leading the list [7][16].